Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Kymera Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 128
- +27 vs. Q2 2022
- Shares held
- 52.8M
- +3.41M (+6.9%) vs. Q2 2022
- Total value
- $1.15B
- +$176.6M (+18.1%) vs. Q2 2022
- New holders
- 36
- 41 more added
- Sold out
- 9
- 34 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYMR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 276 | $11.1B |
| Q1 2026 | 256 | $8.01B |
| Q4 2025 | 255 | $6.99B |
| Q3 2025 | 210 | $4.58B |
| Q2 2025 | 210 | $3.44B |
| Q1 2025 | 174 | $2.00B |
| Q4 2024 | 181 | $2.89B |
| Q3 2024 | 176 | $3.27B |
| Q2 2024 | 157 | $2.01B |
| Q1 2024 | 164 | $2.70B |
| Q4 2023 | 137 | $1.54B |
| Q3 2023 | 122 | $797.2M |
| Q2 2023 | 129 | $1.34B |
| Q1 2023 | 127 | $1.68B |
| Q4 2022 | 121 | $1.40B |
| Q3 2022 | 128 | $1.15B |
| Q2 2022 | 101 | $973.6M |
| Q1 2022 | 126 | $1.93B |
| Q4 2021 | 128 | $2.76B |
| Q3 2021 | 115 | $2.04B |
| Q2 2021 | 110 | $1.29B |
| Q1 2021 | 97 | $887.2M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Kymera Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Charles Schwab Investment Management Inc | 278,560 | $6.07M | 0.00% | +22,018+8.6% | Added |
| FMR LLC | 325,686 | $7.09M | 0.00% | −21,098−6.1% | Reduced |
| Aquilo Capital Management, LLC | 330,246 | $7.19M | 3.02% | +330,246 | New |
| Northern Trust Corp | 331,738 | $7.22M | 0.00% | −1,640−0.5% | Reduced |
| Goldman Sachs Group Inc | 336,759 | $7.33M | 0.00% | +59,495+21.5% | Added |
| Barclays PLC | 352,994 | $7.68M | 0.01% | +119,857+51.4% | Added |
| AJU IB Investment Co., Ltd. | 457,059 | $9.95M | 17.03% | 00.0% | Unchanged |
| Pictet Asset Management SA | 482,001 | $10.5M | 0.02% | −164,074−25.4% | Reduced |
| Candriam Luxembourg S.C.A. | 549,618 | $12.0M | 0.08% | +79,758+17.0% | Added |
| JPMorgan Chase & Co | 561,872 | $12.2M | 0.00% | −41,506−6.9% | Reduced |
| Deer Management Co. LLC | 615,895 | $13.4M | 0.94% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 701,222 | $15.3M | 0.00% | +25,375+3.8% | Added |
| EcoR1 Capital, LLC | 796,093 | $17.3M | 0.51% | +796,093 | New |
| Bank of New York Mellon Corp | 1,025,244 | $22.3M | 0.01% | +582+0.1% | Added |
| Rock Springs Capital Management LP | 1,046,743 | $22.8M | 0.59% | +270,864+34.9% | Added |
| Wasatch Advisors Inc | 1,060,561 | $23.1M | 0.16% | +489,917+85.9% | Added |
| Artal Group S.A. | 1,500,000 | $32.7M | 1.70% | +500,000+50.0% | Added |
| T. Rowe Price Investment Management, Inc. | 1,996,529 | $43.5M | 0.03% | +1,996,529 | New |
| Avoro Capital Advisors LLC | 2,169,230 | $47.2M | 0.87% | +909,230+72.2% | Added |
| State Street Corp | 2,685,404 | $58.5M | 0.00% | −829,034−23.6% | Reduced |
| Vanguard Group Inc | 2,863,177 | $62.3M | 0.00% | −11,547−0.4% | Reduced |
| Redmile Group, LLC | 2,876,637 | $62.6M | 2.43% | +269,507+10.3% | Added |
| Baker Bros. Advisors LP | 2,879,825 | $62.7M | 0.41% | 00.0% | Unchanged |
| BlackRock Inc. | 3,204,682 | $69.8M | 0.00% | +376,248+13.3% | Added |
| Wellington Management Group LLP | 3,410,386 | $74.2M | 0.02% | −1,624,554−32.3% | Reduced |
| Price T Rowe Associates Inc | 4,097,712 | $89.2M | 0.01% | −1,126,974−21.6% | Reduced |
| BVF Inc | 4,692,604 | $102.2M | 4.22% | +553,846+13.4% | Added |
| Atlas Venture Life Science Advisors, LLC | 6,875,698 | $149.7M | 16.52% | 00.0% | Unchanged |
| Bank of Montreal | 0 | $0 | 0.00% | −59,370−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −37,930−100.0% | Sold out |
| First Trust Advisors LP | 0 | $0 | 0.00% | −30,055−100.0% | Sold out |
| ETF Managers Group, LLC | 0 | $0 | 0.00% | −26,611−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −18,426−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −11,800−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −203−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −134−100.0% | Sold out |
| Charter Oak Capital Management, LLC | 0 | $0 | 0.00% | −150−100.0% | Sold out |